Fig. 3: HSCs were depleted from the 27HC treated-HSPCs setting under transplantation stress.

BM cells are pre-treated with 13 µM Cholesterol or 6.2 µM 27OHChol for 48 h, respectively. A Study overview. A 1:1 mixture of CD45.1 test cells (Control vehicle, pre-treated cholesterol, and pre-treated 27HC BM cells) were transplanted with CD45.2 competitor BM cells. B The peripheral blood (PB) was collected and analyzed for CD45.1 chimerism (n = 5). C The frequencies of B cells (B220), T cells (CD3), and Myeloid cells (Myelo, CD11b⁺) from the peripheral blood (PB) of transplant recipients are shown at 12 weeks after transplantation (n = 5). D The BM cells were collected and analyzed for CD45.1 chimerism at 16 weeks after transplantation (n = 5). E The percent of CD45.1 chimerism to indicated populations from the recipients were assessed from the BM cells (LK = Lin⁻Sca1⁻cKit⁺, LKS = Lin⁻Sca1⁺cKit⁺, HPC = Lin⁻Sca1⁺cKit⁺CD48⁺, HSC = Lin⁻Sca1⁺cKit⁺CD150⁺CD48⁻) (n = 5). Data are presented as mean ± SEM. (*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 vs. control; ^#p ≤ 0.05, ^##p ≤ 0.01, and ^###p ≤ 0.001 vs. Chol).